Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Naive Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of moderate to severe low back pain for ≥6 months~* Treating CLBP with a stable daily maintenance dose of non-opioid analgesic medication up to 10 mg morphine sulfate equivalents (MSE) per day for ≥4 weeks. (Additional as needed \[PRN\] non-opioid analgesic medications permitted on top of the stable daily maintenance dose of non-opioid analgesic)~* Stable health, as determined by Principal Investigator~* Are female who are practicing abstinence or using a medically acceptable form of contraception or have been post-menopausal, biologically sterile, or surgically sterile for more than 1 year~* Willing and able to comply with all protocol required visits and assessments~Exclusion Criteria:~* Current cancer related pain or received chemotherapy with 6 months of screening~* Receiving opioid analgesic medication \>10 mg MSE per day within 28 days of screening~* Subjects with a history of other chronic painful conditions~* Reflex sympathetic dystrophy or causalgia, acute spinal cord compression, cauda equina compression, acute nerve root compression, meningitis, or discitis~* Allergy or contraindications to any opioid or acetaminophen~* Surgical procedure for relief of pain with 6 months~* Hypokalemia or clinically unstable cardiac disease, including: unstable atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, or active myocardial ischemia~* QT interval corrected using Fridericia's formula (QTcF) of ≥450 milliseconds on the 12-lead electrocardiogram (ECG)~* History of long QT syndrome or a family member with this condition~* Moderate to severe hepatic impairment~* Moderate to severe renal impairment~* Current or past history of alcohol abuse~* Positive urine toxicology screen for drug of abuse~* History or abnormalities on physical exam, vital signs, electrocardiogram, or laboratory values

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Twice Daily Dosing
- Buprenorphine HCl Buccal Film (Type: EXPERIMENTAL): Twice Daily Dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).